Principal Investigators: Kent Kirshenbaum, PhD
Maxwell is a preclinical stage biotechnology company targeting viral pandemics and other currently untreatable infectious disease. Stanford and NYU scientists invented a new class of broad-spectrum anti-infective therapeutics that attack the virus structure directly.
Maxwell’s CLAROMER™ branded platform develops a diverse family of biostable, low molecular weight compounds which are functional mimics of peptides (“peptidomimetics”) at roughly one-quarter the size and are distinct from macromolecules due to their ability to easily penetrate target membranes.
Maxwell’s vision is to create health for the world safely and affordably.